Business Description
Monopar Therapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US61023L1089
Total Employee Number:
22Description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1243.51 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.4 | |||||
3-Year EPS without NRI Growth Rate | 23.6 | |||||
3-Year FCF Growth Rate | 16.6 | |||||
3-Year Book Growth Rate | 74.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 71.02 | |||||
9-Day RSI | 63.98 | |||||
14-Day RSI | 62.9 | |||||
3-1 Month Momentum % | 103.85 | |||||
6-1 Month Momentum % | 112.5 | |||||
12-1 Month Momentum % | 242.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 33.56 | |||||
Quick Ratio | 33.56 | |||||
Cash Ratio | 33.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -14.92 | |||||
ROA % | -14.59 | |||||
ROIC % | -11840.47 | |||||
3-Year ROIIC % | -3178.87 | |||||
ROC (Joel Greenblatt) % | -11827.81 | |||||
ROCE % | -18.48 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 5.69 | |||||
Price-to-Tangible-Book | 5.69 | |||||
EV-to-EBIT | -27.58 | |||||
EV-to-EBITDA | -27.58 | |||||
EV-to-FCF | -50.08 | |||||
Price-to-Projected-FCF | 35.63 | |||||
| Price-to-Net-Current-Asset-Value | 5.7 | |||||
| Price-to-Net-Cash | 5.72 | |||||
Earnings Yield (Greenblatt) % | -3.63 | |||||
FCF Yield % | -1.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Monopar Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.892 | ||
| Beta | 3.4894 | ||
| 3-Year Sharpe Ratio | 0.66 | ||
| 3-Year Sortino Ratio | 12.63 | ||
| Volatility % | 137.24 | ||
| 14-Day RSI | 62.9 | ||
| 14-Day ATR (€) | 2.761722 | ||
| 20-Day SMA (€) | 97.11 | ||
| 12-1 Month Momentum % | 242.45 | ||
| 52-Week Range (€) | 25.6 - 103.4 | ||
| Shares Outstanding (Mil) | 6.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Monopar Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Monopar Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 84 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 98.60 (+0.20%) | ||
| General meeting for 2026 | 2026-06-22 10:00 | 57.40 (-0.17%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 51.10 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-27 | 48.80 (+1.67%) | ||
| Annual report for 2025 | 2026-03-24 | 48.00 (+2.56%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 70.00 (-0.71%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 33.40 (+0.00%) | ||
| General meeting for 2025 | 2025-06-17 10:00 | 28.00 (-1.41%) | ||
| First quarter earnings results for 2025 | 2025-05-13 | 28.20 (+0.00%) |
Show
Entries
Monopar Therapeutics Inc Frequently Asked Questions
What is Monopar Therapeutics Inc(FRA:1IY0)'s stock price today?
The current price of FRA:1IY0 is €102.60. The 52 week high of FRA:1IY0 is €103.40 and 52 week low is €25.60.
When is next earnings date of Monopar Therapeutics Inc(FRA:1IY0)?
The next earnings date of Monopar Therapeutics Inc(FRA:1IY0) is 2026-11-13 Est..
Does Monopar Therapeutics Inc(FRA:1IY0) pay dividends? If so, how much?
Monopar Therapeutics Inc(FRA:1IY0) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics | 2025-01-23 |
Articles on Monopar Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers